Researchers have discovered a way to program cells to inhibit CRISPR-Cas9 activity. “Anti-CRISPR” proteins had previously been isolated from viruses that infect bacteria, but now University of Toronto and University of Massachusetts Medical School scientists report three families of proteins that turn off CRISPR systems specifically used for gene editing. The work, which appears December 15 in Cell, offers a new strategy to prevent CRISPR-Cas9 technology from making unwanted changes.
“Making CRISPR controllable allows you to have more layers of control on the system and to turn it on or off under certain conditions, such as where it works within a cell or at what point in time,” says lead author Alan Davidson, a phage biologist and bacteriologist at the University of Toronto. “The three anti-CRISPR proteins we’ve isolated seem to bind to different parts of the Cas9, and there are surely more out there.”
CRISPR inhibitors are a natural byproduct of the evolutionary arms race between viruses and bacteria. Bacteria use CRISPR-Cas complexes to target and cut up genetic material from invading viruses. In response, viruses have developed proteins that, upon infection, can quickly bind to a host bacterium’s CRISPR-Cas systems, thus nullifying their effects.
Anti-CRISPR proteins are attractive experimentally because they offer one solution for preventing potential off-target effects. Research in mice has shown that such mistakes may be rare when using CRISPR-Cas9 technology, but even the occasional error could be a serious problem when being used therapeutically in humans.
“CRISPR-Cas9 in ancillary cells, tissues, or organs is at best useless and at worst a safety risk,” says co-author and collaborator Erik J. Sontheimer, a professor in the RNA Therapeutics Institute at the University of Massachusetts Medical School. “But if you could build an off-switch that keeps Cas9 inactive everywhere except the intended target tissue, then the tissue specificity will be improved.”
“Knowing we have a safety valve will allow people to develop many more uses for CRISPR,” says co-author Karen Maxwell, an assistant professor in biochemistry who is also at the University of Toronto. “Things that may have been too risky previously might be possible now.”
While the work will be of great interest to those studying gene editing and gene drives, Davidson’s team is also curious to follow up on the biology of how bacterial CRISPRs and viral anti-CRISPRs interact.
“We didn’t set out to find anti-CRISPRs, we were just trying to understand how phages incorporate themselves into bacterial genomes and stumbled onto something that I think will be important for biotechnology,” Davidson says.
“We were being observant and following a path that we didn’t know where it could lead, and it’s just been a very fun and exciting story.”
Learn more: An anti-CRISPR for gene editing
[osd_subscribe categories=’crispr’ placeholder=’Email Address’ button_text=’Subscribe Now for any new posts on the topic “CRISPR”‘]
Receive an email update when we add a new CRISPR article.
The Latest on: Anti-CRISPR
[google_news title=”” keyword=”anti-CRISPR” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Anti-CRISPR
- A new RNA editing tool could enhance cancer treatmenton February 21, 2024 at 1:44 pm
Cell therapies for cancer can be potentially enhanced using a CRISPR RNA-editing platform, according to a new study published Feb. 21 in Cell. The new platform, Multiplexed Effector ...
- CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Resultson February 20, 2024 at 11:30 pm
CRISPR Therapeutics continues to advance its internally developed targeted conditioning program, an anti-CD117 (c-Kit) antibody-drug conjugate (ADC), through preclinical studies. Additionally, CRISPR ...
- CRISPR-Cas systems articles from across Nature Portfolioon February 20, 2024 at 4:00 pm
CRISPR-Cas systems are prokaryotic immune systems that confer resistance to foreign genetic elements such as plasmids and phages. CRISPR-Cas systems have been exploited for targeted genome editing.
- If You Invested $10,000 in CRISPR Therapeutics in 2019, This Is How Much You Would Have Todayon February 18, 2024 at 10:45 pm
That describes CRISPR Therapeutics (NASDAQ: CRSP) pretty well. The company specializes in gene editing and has made significant progress in the field in recent years. CRISPR's efforts have been ...
- If You Invested $10,000 in CRISPR Therapeutics in 2019, This Is How Much You Would Have Todayon February 18, 2024 at 5:45 pm
CRISPR has been an above-average performer for the last half-decade. The budding biotech made an important breakthrough at the end of last year. CRISPR also has five programs in clinical trials ...
- CRISPR-Cas9 genome editing articles from across Nature Portfolioon February 16, 2024 at 4:00 pm
CRISPR-Cas9 genome editing exploits the CRISPR-Cas system to modify a genome in a targeted manner. Guided by RNA, the Cas9 endonuclease breaks DNA at a target sequence. Imprecise repair of the ...
- iNtRON, Development of PHAGERIA® Anti-Cancer Candidate with Enhanced Antimicrobial Activity by Robot Bacteriophage platform technologyon February 14, 2024 at 7:37 pm
Robot Bacteriophage against microbiome associated with colorectal cancer ▶ Bacteriophage Improvement Platform technology with a broad antimicrobial activity ▶ Proprietary Technology incorporating ...
- New CRISPR Gene-Editing Treatment Approved In Europe For Inherited Blood Disorderson February 13, 2024 at 3:04 am
The European Union on Tuesday approved the world’s first medicine based on CRISPR gene-editing technology to treat two blood disorders, following the U.S. and U.K. in a milestone for the ...
- New CRISPR tool accelerates and optimizes genome editingon February 12, 2024 at 4:00 pm
CRISPR/Cas systems have undergone tremendous advancement in the past decade. These precise genome editing tools have applications ranging from transgenic crop development to gene therapy and beyond.
via Bing News